SUNNYVALE, Calif., May 4, 2005 /PRNewswire-FirstCall via COMTEX/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today multiple presentations and published abstracts regarding Xcytrin(R) (motexafin gadolinium) Injection. The presentations and publications are part of the proceedings at the 2005 American Society of Clinical Oncology Annual Meeting (ASCO) being held May 13-17, 2005, at the Orange County Convention Center in Orlando, FL. The company will have booth #458 in the Exhibit Hall.
The presentations and published abstracts are as follows: Monday, May 16, 2005 Session: Central Nervous System Tumors General Poster Session Title: Validation of Blinded Events Review Committee (ERC)-Determined Time to Neurologic Progression (TTNP) Demonstrates Correlation With Survival, Radiologic Progression, and Functional Independence Endpoints Abstract #1534: 2:00 - 6:00 p.m. Tuesday, May 17, 2005 Symposium: 1:00 p.m. - 3:00 p.m. (EDT) Pharmacyclics is supporting a satellite continuing medical education symposium entitled "Debating Current Issues in Brain Metastases Therapy." This event will be held at the Rosen Plaza, in Grand Ballroom D. Motexafin Gadolinium Published Abstracts Abstract #4724 Title: Phase II Trial of Motexafin Gadolinium (MGd) for Treatment of Metastatic Renal Cell Carcinoma (MRCC) Abstract #3138 Title: Combination Motexafin Gadolinium (MGd) and Docetaxel is Active in Recurrent Lung and Other Solid Tumors: Results of a Phase 1 Trial Abstract #3164 Title: Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel (D) Chemotherapy in the Treatment of Advanced Solid Tumors About Xcytrin
Pharmacyclics is developing Xcytrin as an anti-cancer agent with a novel mechanism of action that is designed to selectively concentrate in tumors and induce apoptosis (programmed cell death). Pharmacyclics has been granted Fast-Track status by the U.S. Food and Drug Administration (FDA) for Xcytrin for the treatment of brain metastases (cancer that has spread to the brain from another part of the body) in non-small cell lung cancer (NSCLC) patients. Xcytrin is currently being evaluated in a randomized Phase 3 clinical trial (the SMART trial) that recently completed enrollment and is designed to compare the effects of whole brain radiation therapy (WBRT) alone to WBRT plus Xcytrin for the treatment of brain metastases in patients suffering from NSCLC. Xcytrin also is currently under investigation in several Phase 1 and Phase 2 clinical trials in various cancers evaluating its use as a single agent and in combination with chemotherapy and/or radiation therapy.
Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and atherosclerosis. The company's products are rationally designed, ring-shaped small molecules called texaphyrins that are designed to selectively target and disrupt the bioenergetic processes of diseased cells, such as cancer and atherosclerotic plaque. More information about the company, its technology, and products in development can be found on its website at www.pharmacyclics.com.
NOTE: Pharmacyclics(R), Xcytrin(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.
SOURCE Pharmacyclics, Inc.
Leiv Lea of Pharmacyclics, Inc., +1-408-774-0330; or Carolyn Bumgardner Wang of WeissComm Partners, +1-415-946-1065
Copyright (C) 2005 PR Newswire. All rights reserved.
News Provided by COMTEX